In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Where 2020 saw the development and testing of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …

Objective To compare the efficacy of covid-19 vaccines between immunocompromised and
immunocompetent people. Design Systematic review and meta-analysis. Data sources …

A Third Vaccine Dose in Organ-Transplant Recipients It is known that people receiving
immune suppressive therapy, such as recipients of solid-organ transplants, have a …

Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson)
Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising …

The emerging SARS-CoV-2 variants of concern (VOCs) threaten the effectiveness of current
COVID-19 vaccines administered intramuscularly and designed to only target the spike …

The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent
individuals,–. Despite the reduced protection from infection, individuals who received three …

The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may
compromise vaccine effectiveness and the ability of antibodies triggered by previous …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …